Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Citigroup

Key Points

• Citigroup has raised the price target for Gilead Sciences from $125.00 to $135.00, indicating a potential upside of 15.60% from the company's previous close.
• The company reported $2.01 earnings per share for the last quarter, exceeding analysts' expectations of $1.96, with revenue also above estimates at $7.08 billion.
• Research analysts maintain a consensus rating of "Moderate Buy" for Gilead, with 21 analysts giving a Buy rating and an average target price of $117.67.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective upped by Citigroup from $125.00 to $135.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price target indicates a potential upside of 15.60% from the company's previous close.

A number of other research firms have also recently commented on GILD. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $117.67.

Gilead Sciences Trading Up 2.8%

NASDAQ:GILD opened at $116.78 on Wednesday. The business's 50-day moving average is $114.41 and its two-hundred day moving average is $110.06. The firm has a market capitalization of $144.90 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. Gilead Sciences has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. The trade was a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $9,402,130. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

Several hedge funds have recently made changes to their positions in the stock. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the first quarter worth $25,000. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the period. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $27,000. Finally, Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $29,000. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.